The selection frequencies of cefepime (BMY 28142), ceftazidime, and cefotaxime resistance among Pseudomonas aeruginosa strains were determined. Cefepime-resistant mutants were not selected by cefepime (frequency, <10-11). Ceftazidime-and cefotaxime-resistant mutants were isolated at frequencies of 10-5 to 10 10 and were often cross-resistant. However, cefepime resistance among ceftazidime-and cefotaximeresistant mutants was rare. Selected mutants resistant to cefepime constitutively produced 40-to 450-fold more I8-lactamase than did the parent strain.
I8-lactamase than did the parent strain.
We recently observed that only six percent of ceftazidimeand/or cefotaxime-resistant clinical isolates of members of the family Enterobacteriaceae and Pseudomonas aeruginosa were resistant to cefepime (BMY 28142) (manuscript in preparation). In fact, all cefepime-resistant isolates belonged to the species P. aeruginosa and were resistant to ceftazidime and cefotaxime. This observation suggested that resistance to extended-spectrum cephalosporins may be a prerequisite to cefepime resistance. In other words, multiple mutations may be necessary to achieve resistance of cefepime. Indeed, in Escherichia coli two or more genetic events were required to attain the high 1-lactamase level necessary to achieve resistance to the more stable ,B-lactams cefuroxime and cefamandole as compared with cephalothin and ampicillin (6) . In this communication we report the frequencies of mutations conferring resistance to cefepime, ceftazidime, and cefotaxime in P. aeruginosa.
Three cefepime-susceptible strains of P. aeruginosa were examined: strain A21213, which was susceptible to ceftazidime and cefotaxime; strain A20599, which was susceptible to ceftazidime but resistant to cefotaxime; and strain A26401, which was resistant to ceftazidime and cefotaxime (Table 1) . Strains A21213 and A20599 produce inducible type Id P-lactamase, and strain A26401 is a derepressed producer of type Id ,B-lactamase (see below). Antimicrobial activity was measured by the National Committee for Clinical Laboratory Standards agar dilution technique with MuellerHinton agar; ca. 5 x 105 CFU was delivered per spot with a multiprong inoculator (5) .
The frequency of mutation to drug resistance was determined by inoculating known bacterial concentrations onto Mueller-Hinton agar containing drug at 4x, 8x, and 16X MIC. The plates were incubated at 35°C for 2 days to allow for any minute colonies to grow. Up to 32 colonies growing on the highest drug concentration was subcultured onto individual blood agar plates for single-colony isolation. The MIC of the selective cephalosporin was then determined for each isolate to identify resistant mutants. The mutants were also tested against other cephalosporins to determine the frequency of cross-resistance development. All MICs were determined in triplicate.
With cefepime as the selective agent, no cefepime-resistant mutants were isolated (Table 1 ). The frequency of * Corresponding author. mutation to ceftazidime resistance, between l0-5 and 10-10 for strain A20599, was concentration dependent. In contrast, the frequency of selection for ceftazidime resistance with strain A21213 was in the 10' range at all three concentrations tested. In all instances, the ceftazidime and cefotaxime MICs for ceftazidime-resistant mutants were increased at least 32-fold. On the other hand, ceftazidime-resistant mutants with increased cefepime MIC exhibited only a fourfold increase in cefepime MIC compared with that for the parental strain. In strain A21213, the frequencies of obtaining cefotaxime-resistant mutants were 10-5 to 10-6 (Table 1) .
Again, cefotaxime-resistant mutants were often resistant to ceftazidime. Cefotaxime-resistant mutants seldom showed increased cefepime MICs and were never cefepime resistant ( Table 2 ). The frequencies of mutation to cefotaxime resistance were not determined for strains A20599 and A26401, nor was the frequency of mutation to ceftazidime resistance for strain A26401, since these strains were already resistant to these agents.
Strains A21213 and A20599 were inducible producers of ,B-lactamases (Table 3) with pIs of 9.0 and 8.5, respectively, as determined by isoelectric focusing (8) . Strain A26401 constitutively produced a ,-lactamase (pl 8.5) at levels approximately equal to that produced by A20599 after induction. The three mutants selected by ceftazidime from A20599 showed a change from inducible to derepressed production of the pl 8.5 ,-lactamase at levels equivalent to (A20599-10) that inducible in the parent or 1 order of magnitude higher (A20599-15 and A20599-17). All three yielded minor satellite bands on isoelectric focusing with slightly lower pls than 8.5, and A20599-17 produced a second ,B-lactamase (pl 8.8). The latter 1-lactamase has also been seen in some clinical isolates (unpublished data), and the possible relationship with the pl 8.5 P-lactamase is under investigation.
The difference in MICs of cefotaxime for A21213 and A20599 probably cannot be explained on the basis of ,Blactamase levels alone, unless there is a difference in inducibility of the ,B-lactamases by cefotaxime or some other component of susceptibility to cephalosporins is more critical in the latter strain. The selection of cefepime resistance from strain A20599 and not A21213 is also indicative of another component of cephalosporin susceptibility playing a more critical role in the former strain. The MIC of ceftazidime was increased 32 or >64-fold for all three mutants of ANTIMICROB. AGENTS CHEMOTHER. The present study shows that spontaneous mutation of cefepime resistance is extremely low in P. aeruginosa. Cefepime-resistant mutants were not isolated in this study in the presence of cefepime and were only seldom'isolated by using other cephalosporins for selection. Mutants resistant to ceftazidime and cefotaxime were much more readily selected and were generally cross-resistant. Sanders and Sanders examined the ability of cephalosporins to select for derepressed mutants for P-lactamases by using various members of the family Enterobacteriaceae and P. aeruginosa (10) . Among the cephalosporins tested, they observed that the in vitro activity of cefepime was least affected. The percent of derepressed mutants susceptible to cefepime (96%) was the same as for wild-type organisms, whereas 24 to 32% of derepressed mutants were susceptible to cefotaxime and ceftazidime versus 88 to 96% of the wild-type organisms. This difference in their selection ability is probably unrelated to their abilities to induce P-lactamases, since cefepime, cefotaxime, and ceftazidime are all poor enzyme inducers (10) . In addition, this difference does not reflect their ability to kill bacteria; cefepime does not show a significantly enhanced killing rate versus ceftazidime (unpublished observation). Also, none of these strains was found to produce additional -lactamases with pIs consistent with those of the plasmid-encoded P-lactamases TEM-3 (CTX-1 [1] ), SHV-2 (2), or CAZ-1 (7), which have been associated with resistance of Klebsiella pneumoniae, K. ozaenae, and Serratia marcescens to extended-spectrum caphalosporins.
A possible explanation for a lower selection incideplce to cefepime resistance is that multiple mutations are required. In E. coli, increased P-lactamase levels which can lead to increased 13-lactam MICs may be achieved by either increasing the copy number of the P-lactamase structural gene ampC or by increasing the transcriptional rate of ampC through enhanced promotor efficiency or decreased premature termination at the attenuator site (3 (4) . Whether the use of cefepime as a first-line antibiotic will avoid in vivo development of resistance to ,B-lactamase-stable cephalosporins will require consideration in clinical trials. b Growth in 10 pg of cefoxitin per ml for 2 h before harvest.
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